ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
20 hedge funds and large institutions have $9.66M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
18% more capital invested
Capital invested by funds: $8.17M → $9.66M (+$1.49M)
7.95% more ownership
Funds ownership: 39.81% → 47.76% (+7.9%)
5% more funds holding
Funds holding: 19 → 20 (+1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$2.8M |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
+$257K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$244K |
| 4 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$146K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$752K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$262K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$107K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$105K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$34.7K |
CNCR Hedge Fund Activity: Q4 2022 in Review
20 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2022, worth a combined $9.66M — up 18% from $8.17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNCR positions and 4 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was BCWM LLC, adding an estimated $2.8M. The largest seller was Jane Street, exiting entirely with an estimated $752K sold.
- 20 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2022, up from 19 in Q3 2022.
- Funds reported $9.66M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2022, up 18% quarter-over-quarter.
- 6 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2022 and 4 closed out, a net change of +2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2022 was BCWM LLC, an estimated $2.8M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2022 was Jane Street, an estimated $752K sold.
Based on aggregated 13F filings for Q4 2022.